Novavax begins several rolling regulatory reviews for its COVID-19 vaccine

By The Science Advisory Board staff writers

February 5, 2021 -- Novavax has started the rolling review process for authorization of its COVID-19 vaccine, NVX-CoV2373, by multiple regulatory agencies.

The reviews will continue while the company completes its phase III clinical trials in the U.K. and U.S. of its recombinant protein-based vaccine candidate.

To date, Novavax has begun a rolling review with the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.